Intelligence Profile
Safety Profile
Evidence Limitations: The safety profile of NAD+ IV therapy is based on extremely limited clinical evidence. Only one direct study was identified examining intravenous NAD+ infusion tolerability, which appears to be a small retrospective pilot study. The majority of available evidence comes from studies of related compounds (nicotinamide riboside, nicotinamide mononucleotide) or unrelated research.
Known Side Effects:
Based on the limited evidence available, specific side effects of NAD+ IV infusion have not been comprehensively documented in peer-reviewed literature. The identified retrospective tolerability study examining intravenous NAD+ versus nicotinamide riboside may contain relevant safety data, but detailed findings are not available in the provided evidence.
Contraindications:
No specific contraindications for NAD+ IV therapy have been established in the clinical literature based on the available evidence.
Drug Interactions:
No documented drug interactions specific to intravenous NAD+ administration were identified in the provided evidence.
High-Risk Populations:
Without adequate clinical safety data, it is unclear which populations should avoid NAD+ IV therapy. Standard precautions would suggest careful consideration in:
- Pregnant or breastfeeding individuals
- Patients with kidney or liver dysfunction
- Individuals with cardiovascular conditions
- Those taking multiple medications
Clinical Trial Safety Data:
While several clinical trials are examining NAD+ precursors or related compounds (including "Coenzyme I for Injection"), these studies are either still recruiting participants or investigating different formulations, limiting available safety conclusions for NAD+ IV specifically.
Important Safety Considerations:
The lack of robust safety data for NAD+ IV therapy is concerning. Intravenous administration of any compound carries inherent risks including infection, vein irritation, and potential systemic reactions. The absence of well-documented safety profiles, standardized dosing protocols, or regulatory approval for this specific indication raises significant safety questions.
This information is for educational purposes only and does not constitute medical advice. Consult with a healthcare provider before considering any IV therapy, especially given the limited safety evidence for NAD+ infusions.